Latest Commercial Operations News

Frontier Energy unveils an ambitious multi-stage expansion of its Waroona Renewable Energy Project, targeting 1GW of solar and 660MW of battery storage to support Western Australia’s coal phase-out.

Echo IQ’s application for a Category III CPT code was declined by the AMA, but the company is exploring reconsideration and new AI-specific coding frameworks to advance US reimbursement.

Papyrus Australia has appointed Daniel Schmidt as CEO and secured a $250k government grant alongside a binding agreement to produce biodegradable mining products, marking a decisive shift from R&D to commercial operations.

Memphasys Limited has secured $0.84 million through a placement and announced a rights issue to raise up to $1.12 million, sharply cutting operating costs to accelerate commercialisation and manufacturing scale-up of its Felix™ bioseparation system.

Talga Group has signed a strategic cooperation agreement with United Catalyst Corporation, marking its entry into the US battery anode market and setting the stage for new graphite recycling and anode production facilities in South Carolina.

Metallium Ltd has appointed former U.S. Deputy Assistant Secretary of Defense Travis Langster to its U.S. advisory board, aiming to strengthen ties with government and industry for critical metals supply chain resilience.

Osteopore Limited reported a 6% increase in revenue to $1.56 million for the half-year ended June 2025, alongside a slight rise in net loss driven by expanded product development and compliance costs. The company secured key regulatory approvals and broadened its distribution footprint in Asia and the US.

Adherium Limited reported a $12.68 million net loss for FY2025 as it pivots towards commercialising its smart inhaler technology in the US, supported by a $4.49 million capital raise.

Janus Electric Holdings reported a steep 94% rise in net loss to $8.7 million for FY2025, impacted by a disruptive battery recall and significant restructuring costs. The company completed a reverse takeover, raised $8.8 million, and secured a $5 million MOU for African expansion, signaling a bold shift toward heavy transport electrification.

MedAdvisor reported a 36% revenue drop in FY25, driven by US health program setbacks, and sold its ANZ business to focus on restructuring its US operations.

BCAL Diagnostics has launched its first commercial breast cancer diagnostic test, BREASTESTplus™, in Australia, marking a key milestone despite a $7.24 million loss for FY2025. The company is also advancing its US operations with a new subsidiary and clinical trials underway.

Clinuvel Pharmaceuticals has reported its ninth consecutive year of revenue and profit growth, driven by strong sales of SCENESSE® and strategic investment in vitiligo clinical trials. The company also declared its eighth consecutive dividend, underscoring financial resilience.